These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 37527005)
1. Investigating the human and nonobese diabetic mouse MHC class II immunopeptidome using protein language modeling. Hartout P; Počuča B; Méndez-García C; Schleberger C Bioinformatics; 2023 Aug; 39(8):. PubMed ID: 37527005 [TBL] [Abstract][Full Text] [Related]
2. BERTMHC: improved MHC-peptide class II interaction prediction with transformer and multiple instance learning. Cheng J; Bendjama K; Rittner K; Malone B Bioinformatics; 2021 Nov; 37(22):4172-4179. PubMed ID: 34096999 [TBL] [Abstract][Full Text] [Related]
3. The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM. Peterson M; Sant AJ J Immunol; 1998 Sep; 161(6):2961-7. PubMed ID: 9743359 [TBL] [Abstract][Full Text] [Related]
4. A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes. Gregori S; Trembleau S; Penna G; Gallazzi F; Hammer J; Papadopoulos GK; Adorini L J Immunol; 1999 Jun; 162(11):6630-40. PubMed ID: 10352280 [TBL] [Abstract][Full Text] [Related]
5. Prevention of insulin-dependent diabetes mellitus in nonobese diabetic mice by immunogenic but not by tolerated peptides. Vaysburd M; Lock C; McDevitt H J Exp Med; 1995 Sep; 182(3):897-902. PubMed ID: 7650494 [TBL] [Abstract][Full Text] [Related]
6. DeepMHCII: a novel binding core-aware deep interaction model for accurate MHC-II peptide binding affinity prediction. You R; Qu W; Mamitsuka H; Zhu S Bioinformatics; 2022 Jun; 38(Suppl 1):i220-i228. PubMed ID: 35758790 [TBL] [Abstract][Full Text] [Related]
7. The I-Ag7 MHC class II molecule linked to murine diabetes is a promiscuous peptide binder. Stratmann T; Apostolopoulos V; Mallet-Designe V; Corper AL; Scott CA; Wilson IA; Kang AS; Teyton L J Immunol; 2000 Sep; 165(6):3214-25. PubMed ID: 10975837 [TBL] [Abstract][Full Text] [Related]
8. Self peptides isolated from MHC glycoproteins of non-obese diabetic mice. Reich EP; von Grafenstein H; Barlow A; Swenson KE; Williams K; Janeway CA J Immunol; 1994 Mar; 152(5):2279-88. PubMed ID: 8133041 [TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of the diabetes-associated mouse MHC class II protein, I-Ag7. Reizis B; Eisenstein M; Bocková J; Könen-Waisman S; Mor F; Elias D; Cohen IR Int Immunol; 1997 Jan; 9(1):43-51. PubMed ID: 9043946 [TBL] [Abstract][Full Text] [Related]
10. The MHC class II molecule I-Ag7 exists in alternate conformations that are peptide dependent. Arneson LS; Peterson M; Sant AJ J Immunol; 2000 Aug; 165(4):2059-67. PubMed ID: 10925290 [TBL] [Abstract][Full Text] [Related]
11. Nonobese diabetic mice display elevated levels of class II-associated invariant chain peptide associated with I-Ag7 on the cell surface. Bhatnagar A; Milburn PJ; Lobigs M; Blanden RV; Gautam AM J Immunol; 2001 Apr; 166(7):4490-7. PubMed ID: 11254705 [TBL] [Abstract][Full Text] [Related]
12. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. Nielsen M; Lundegaard C; Lund O BMC Bioinformatics; 2007 Jul; 8():238. PubMed ID: 17608956 [TBL] [Abstract][Full Text] [Related]
13. High-resolution analysis of the murine MHC class II immunopeptidome. Sofron A; Ritz D; Neri D; Fugmann T Eur J Immunol; 2016 Feb; 46(2):319-28. PubMed ID: 26495903 [TBL] [Abstract][Full Text] [Related]
14. A self MHC class II beta-chain peptide prevents diabetes in nonobese diabetic mice. Chaturvedi P; Agrawal B; Zechel M; Lee-Chan E; Singh B J Immunol; 2000 Jun; 164(12):6610-20. PubMed ID: 10843721 [TBL] [Abstract][Full Text] [Related]
15. The murine diabetogenic class II histocompatibility molecule I-Ag7: structural and functional properties and specificity of peptide selection. Suri A; Unanue ER Adv Immunol; 2005; 88():235-65. PubMed ID: 16227092 [TBL] [Abstract][Full Text] [Related]
16. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Latek RR; Suri A; Petzold SJ; Nelson CA; Kanagawa O; Unanue ER; Fremont DH Immunity; 2000 Jun; 12(6):699-710. PubMed ID: 10894169 [TBL] [Abstract][Full Text] [Related]
17. RPEMHC: improved prediction of MHC-peptide binding affinity by a deep learning approach based on residue-residue pair encoding. Wang X; Wu T; Jiang Y; Chen T; Pan D; Jin Z; Xie J; Quan L; Lyu Q Bioinformatics; 2024 Jan; 40(1):. PubMed ID: 38175759 [TBL] [Abstract][Full Text] [Related]
18. The motif for peptide binding to the insulin-dependent diabetes mellitus-associated class II MHC molecule I-Ag7 validated by phage display library. Gregori S; Bono E; Gallazzi F; Hammer J; Harrison LC; Adorini L Int Immunol; 2000 Apr; 12(4):493-503. PubMed ID: 10744651 [TBL] [Abstract][Full Text] [Related]
19. MHCII-peptide presentation: an assessment of the state-of-the-art prediction methods. Yang Y; Wei Z; Cia G; Song X; Pucci F; Rooman M; Xue F; Hou Q Front Immunol; 2024; 15():1293706. PubMed ID: 38646540 [TBL] [Abstract][Full Text] [Related]
20. Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide. Hurtenbach U; Lier E; Adorini L; Nagy ZA J Exp Med; 1993 May; 177(5):1499-504. PubMed ID: 8478620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]